Digital Sponsored Ethical AI & trust-driven innovation: UCB’s Erik Janssen How can pharma lead the way in ethical AI and trust-driven innovation?
News White House signs pricing deals with nine more pharmas Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
R&D Sponsored 12 Questions With Marie Teil Marie Teil is a pharmaceutical executive with over 20 years of experience in the healthcare field. She leads UCB's Women of Childbearing Age programme
News UCB buys T-cell therapy biotech Candid for $2bn upfront Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
